A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

An expert discusses how adjuvant therapy options for high-risk muscle-invasive bladder cancer (MIBC); ypT2-ypT4a or N+) ...

An expert discusses how patients with muscle-invasive urothelial carcinoma (MIUC) undergoing radical cystectomy face a ...

An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the ...

Geoffrey Shouse, DO, PhD, discusses the growing interest in bispecific antibodies within the field of oncology.

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of multiple myeloma after quadruplet frontline with transplant.

A panelist discusses how low baseline EBV levels still showed benefit from toripalimab in JUPITER-02, though EBV status influences treatment decisions and alternative markers are needed for ...

A panelist discusses how the unclear request format creates ambiguity about which case is being referenced, making it difficult to provide specific details that stand out without additional context.

A panelist discusses A panelist discusses how the integration of immunotherapy with chemotherapy as first-line treatment for recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) is transforming ...

A panelist discusses how community practitioners should monitor for immune-related adverse events when using toripalimab for recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC), establish clear ...

Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer.

Panelists discuss the presentation and management of a case involving metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration, focusing on treatment approaches and clinical consideration ...